HONG KONG – Dong-A ST. Co. Ltd., an 84-year-old South Korean pharmaceutical company, recently inked two separate licensing agreements with Nasdaq-listed Tobira Therapeutics Inc., as a further sign that Korean firms are reaching deeper into the global biopharma scene through licensing agreements with multinationals.